Gsk Share Discussion Threads

[patientcapital] 24/1/2022 18:41

£37 - 48bn according to the scribblers. Unilever offered no premium. Quite rightly rejected.

[jonjoneil] 24/1/2022 17:01

Don't see how she screwed up. The GSK BoD would have known that ULVR shareholders would reject the deal on price. It was the dope Jope who screwed up.

[rogerrail] 24/1/2022 15:47

Fat chance, at over 19 x EBITDA its a bit rich. IMO it will be valued between 40 - 45 billion.Emma screwed up.

[spoole5] 24/1/2022 15:21

All focus on ULVR now, Emma missed the boat

[redtom1] 20/1/2022 15:38

Spoole5,
To suggest that this will be listed 'way below 50bn' is ridiculous. This deal may have fallen over but 50bn was on the table and analysts are suggesting it is worth at least that. A listing is our best way to realise value for both parts.

[jonjoneil] 20/1/2022 15:32

NY still over $45. Not reflecting the big drop here.(yet) Equiv to £16.48

[spoole5] 20/1/2022 15:22

I mean from anyone. This will be listed way below 50bn

[jonjoneil] 20/1/2022 15:12

Nor does any other rational thinking person. The CEO of Unilever deserves to lose his job for misjudging his shareholders so badly.

[spoole5] 20/1/2022 14:21

Market does not believe further bids are coming.

[philanderer] 20/1/2022 14:04

SP below last friday's close now.

[beergut] 20/1/2022 11:18

Could the whole of GSK now be in play with the buyer knowing they can get 50 billion for the toothpaste division

[quepassa] 20/1/2022 10:59

Price tag £60bn.


This is going to the highest bidder whether by private sale or by market spin-off.


Remains in play.


all imo. dyor.
qp

[tradermichael] 20/1/2022 10:55

Pierre, I agree with all of your points made. I sold a tranche of GSK on Monday @1727p, but I'm watching the movements for a re-entry!

[medieval blacksmith] 20/1/2022 10:43

Med has been saying here that the most likely best investment here medium/long term is using event/spin-off arbitrage to purchase the health care/consumer goods business using pharma share sells towards purchase cost. I did sell the other day because the whole interest by Unilever and shareholders seemed very weak - an almost none event (so far).

Years ago I told GSK investors that if you are interested in GSK you would be better buying AZN and Reckitt. .

I read a good comprehensive report that showed total returns on collective pharma are now pretty much lower than the costs of capital. This means you have to be VERY selective on which pharma companies you have and hope you choose the right ones. The increasing hurdles to get new drugs accepted against the added value they have versus existing drugs (including generics and 'clones') is making returns difficult when early stage pharma is being bought for ridiculous sums and PEs. The money to be made here now is generally in the hands of elite investors and PE groups - pop stars and the likes.

As always 'us plebs' get to fight over the left overs.

[careful] 20/1/2022 10:41

an increase ulvr share price is sweetening the deal.
they report on feb 4.

[tornado12] 20/1/2022 10:35

PO , I certainly agree with your last comment, there could be gold at the end of this rainbow & Im a firm hold

[pierre oreilly] 20/1/2022 10:30

Not sure why everyone thinks this is all over. Maybe, but it may not be, we have no info to go on.

The suitor saying 'we're pulling out' means absolutely fa. They are hardly going to say 'hang on while we see how much more to offer you'.

Just a 50/50 gamble one way or the other.

Those who sold at the top will be looking to buy back in here I expect, although no amount of pi trading will shift this.

I'm holding, even the split may result in the two being worth more than than the one, and certainly there'd be much more chance of a takeover of one or the other. That's the worst case i can see atm.

[tornado12] 20/1/2022 10:23

TBH I wouldn’t trust Emma with £50 billion of our cash so for me is the right outcome and we go on with the split. I want to have shares in both for the long term and believe Emma will not be around forever holding back the potential of the business … pharma would thrive with better leadership and vision

[spoole5] 20/1/2022 08:54

Emma overplayed her hand.

[spyder] 20/1/2022 08:47

Congratulations to all who took profits at >£17, I should have done too but I was cautiously optimistic that there was more to come. Perhaps one day but we are stuck below £17 now for the foreseeable. Perhaps £17 will be seen as the high water mark in this current escapade?
I feel for anyone who bought shares on Monday in the hope of a positive outcome with the Consumer Division - never underestimate the capacity for GSK to disappoint!

[spoole5] 20/1/2022 08:10

Very much doubt consumer will achieve anything near 50bn on listing, no other bidders, should have tried to get an all cash offer.

[philanderer] 20/1/2022 00:22

GSK loses its biggest fish - now can under-fire boss Walmsley survive the activist assault?

[philanderer] 20/1/2022 00:20

Unilever insists it won't pay a penny more than £50bn for GSK's consumer healthcare arm


Bruno Monteyne, analyst at City broker Bernstein, said Unilever was ‘trying to control the narrative’.

He said: ‘Rather than having the deal refused by investors it is better not to let it get to that stage. This gives them an exit, meaning it looks like it is their decision not to go any further.

‘But that is damage limitation the market will see through. Many questions will be asked in terms of how they came up with this and the valuation, what else is wrong with the business?’

But he suggested that GSK bosses may also be ‘kicking themselves’, having overplayed their hand trying to flush out a higher offer.

[roybel] 19/1/2022 18:21

Has anyone been called from the US and been offered £25 - 30/share ?

[patientcapital] 19/1/2022 18:01

Rightly so. Before embarking on such adventures it would be advisable to ask the boss (significant shareholders) first.